



Published in final edited form as:

*Oncogene*. 2017 May 11; 36(19): 2693–2703. doi:10.1038/onc.2016.422.

## Hic-5 Remodeling of the Stromal Matrix Promotes Breast Tumor Progression

Gregory J. Goreczny<sup>1</sup>, Jessica L. Ouderkerk-Pecone<sup>1</sup>, Eric C. Olson<sup>2</sup>, Mira Krendel<sup>1</sup>, and Christopher E. Turner<sup>1,\*</sup>

<sup>1</sup>Department of Cell and Developmental Biology, State University of New York Upstate Medical University, Syracuse, New York, 13210, United States

<sup>2</sup>Department of Neuroscience and Physiology, State University of New York Upstate Medical University

### Abstract

The remodeling of the stromal extracellular matrix (ECM) plays a crucial, but incompletely understood role during tumor progression and metastasis. Hic-5, a focal adhesion scaffold protein, has previously been implicated in tumor cell invasion, proliferation and metastasis. To investigate the role of Hic-5 in breast tumor progression *in vivo*, Hic-5<sup>-/-</sup> mice were generated and crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) mouse. Tumors from the Hic-5<sup>-/-</sup>;PyMT mice exhibited increased latency and reduced growth, with fewer lung metastases, as compared to Hic-5<sup>+/-</sup>;PyMT mice. Immunohistochemical analysis showed that Hic-5 is primarily expressed in the cancer associated fibroblasts (CAFs). Further analysis revealed that the Hic-5<sup>-/-</sup>;PyMT tumor stroma contains fewer CAFs and exhibits reduced ECM deposition. The remodeling of the stromal matrix by CAFs has been shown to increase tumor rigidity to indirectly regulate FAK Y397 phosphorylation in tumor cells to promote their growth and invasion. Accordingly, the Hic-5<sup>-/-</sup>;PyMT tumor cells exhibited a reduction in FAK Y397 phosphorylation. Isolated Hic-5<sup>-/-</sup>;PyMT CAFs were defective in stress fiber organization and exhibited reduced contractility. These cells also failed to efficiently deposit and organize the ECM in two and three dimensions. This, in turn, impacted three dimensional MDA-MB-231 tumor cell migration behavior. Thus, using a new knockout mouse model, we have identified Hic-5 expression in CAFs as a key requirement for deposition and remodeling of the stromal ECM to promote non-cell autonomous breast tumor progression.

### Keywords

Paxillin; TGFB1i1; Focal Adhesion; Extracellular Matrix; Remodeling; MMTV-PyMT

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Correspondence: Department of Cell and Developmental Biology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, Telephone: 315-464-8598, Fax: 315-464-8535, [turnerce@upstate.edu](mailto:turnerce@upstate.edu).

### Conflict of Interest

The authors declare no conflict of interest.

Supplementary information accompanies the paper on the *Oncogene* website (<http://www.nature.com/onc>)

## Introduction

Normal tissue stroma is rich in fibroblasts that constantly sense the extracellular environment to regulate normal tissue homeostasis<sup>1</sup>. However, these fibroblasts can differentiate into cancer associated fibroblasts (CAFs) upon receiving signals from transformed epithelial cells or through altered ECM composition<sup>2</sup>. The resulting contractile  $\alpha$ -Smooth Muscle Actin (SMA) positive cells can then promote tumor cell growth through paracrine signaling, as well as protease- and force-dependent reorganization of the stromal matrix<sup>3,4</sup>. The extracellular matrix (ECM) provides structural support to cells and is rich in growth factors<sup>5</sup>. Furthermore, during tumor progression, linearization of the ECM fibers at the invasive front of the tumor has been suggested to facilitate tumor cell invasion into the surrounding tissue and dissemination into the bloodstream<sup>6</sup>. Indeed, the density of the stromal matrix is a prognostic indicator of human breast tumors, suggesting that organization of the stroma can promote tumorigenesis<sup>7</sup>. Consistent with this premise, tumor formation is elevated in a mouse model expressing a collagen I mutant that is resistant to degradation, resulting in an accumulation of stromal matrix<sup>8</sup>. Furthermore, overexpression of the collagen cross-linker, lysyl oxidase, in fibroblasts can directly promote tumorigenesis and metastasis through enhanced focal adhesion signaling<sup>9</sup>. Therefore, it is critical to understand the mechanisms of CAF differentiation and ECM reorganization and their role during tumor malignancy.

Focal adhesions are sites of cell adhesion to the ECM that play a key role in mechanosensing by transducing signals from the ECM to regulate cell behavior<sup>10</sup>. The focal adhesion scaffold/adaptor protein, Hic-5 (TGF $\beta$ 1i1), is a member of the paxillin family of LIM domain proteins that has previously been implicated in skin fibroblast contractility and hypertrophic scar tissue formation<sup>11,12</sup>. Although Hic-5 and paxillin share extensive homology and many of the same binding partners, they have distinct yet overlapping functions. For example, paxillin and Hic-5 have differing roles in regulating tumor cell plasticity, as well as spatiotemporal regulation of Rac1 and RhoA activity<sup>13,14</sup>. Furthermore, in contrast to paxillin<sup>-/-</sup> mice, which die in utero<sup>15</sup>, Hic-5<sup>-/-</sup> mice, described herein are fertile and viable. Interestingly, analysis of gene expression profiles from human breast cancer patients shows Hic-5 is preferentially upregulated in the CAFs, suggesting that Hic-5 may play a crucial role in fibroblast function during tumor progression<sup>16</sup>. Hic-5 has also been implicated in other aspects of tumor progression including epithelial to mesenchymal transition (EMT) and invadopodia formation to promote cell invasion *in vitro*<sup>17,18</sup>. However, the role of Hic-5 during breast tumor progression, *in vivo*, has yet to be elucidated.

To further interrogate the role of Hic-5 during breast tumor progression, we crossed the Hic-5<sup>-/-</sup> mouse with the MMTV-PyMT transgenic mouse, a well-established model for human breast cancer progression<sup>19</sup>. Importantly, while we observed no significant Hic-5 expression in the primary tumor cells, its robust expression in tumor CAFs contributed indirectly to tumor growth, invasion and metastasis through promoting the deposition and remodeling of the stromal matrix.

## Results

### Hic-5 expression in the stroma is required for tumor growth

Prior to analyzing the role of Hic-5 during breast tumor progression, we evaluated whether Hic-5 is required for normal breast development. Tissue sections of mammary glands from 6 week old Hic-5<sup>+/-</sup> and Hic-5<sup>-/-</sup> mice were stained for Hic-5 (Supplementary Figure 1A). Hic-5 expression was localized to myoepithelial cells (arrowhead), tissue stroma (arrow) and blood vessels (asterisk). To assess whether Hic-5 plays a role in mammary gland development, whole mounts of mammary glands from 6-week old mice were analyzed, revealing that the ducts from the Hic-5<sup>-/-</sup> mice have reduced penetration into the fat pad (Supplementary Figure 1B,C). However, by 10-weeks of age, there was no significant difference in the penetration of the ducts into the fat pad (Supplementary Figure 1D,E), suggesting that although Hic-5 may play a role in the rate of normal mammary gland development, the glands are able to fully develop in the absence of Hic-5.

To determine if the loss of Hic-5 expression impacts mammary tumor progression *in vivo*, we utilized the Mouse Mammary Tumor Virus–Polyoma Virus Middle T-Antigen (MMTV-PyMT) mouse model. The MMTV-PyMT mouse model goes through similar stages of tumor progression as human breast cancer, including stage progression, with consistent biomarker expression, and therefore provides a widely accepted model to understand human disease<sup>19</sup>. To assess whether the lack of Hic-5 impacts tumor onset and growth, the tumors were monitored weekly. The onset of palpable tumor formation was slightly delayed, while the growth of the primary tumor was significantly reduced in the absence of Hic-5 (Figure 1A,B). We observed no significant difference in tumor latency and growth rate between the Hic-5<sup>+/+</sup>;PyMT and Hic-5<sup>+/-</sup>;PyMT mice (data not shown). Thus, we compared only the Hic-5<sup>-/-</sup>;PyMT mice to Hic-5<sup>+/-</sup>;PyMT mice throughout the study. Western blot analysis of whole tumor lysates confirmed that Hic-5 is not expressed in the Hic-5<sup>-/-</sup>;PyMT tumors as compared to the Hic-5<sup>+/-</sup>;PyMT tumors (Figure 1C). Furthermore, western blotting for the family member, paxillin, revealed that there was no significant change in expression in the primary tumor (Figure 1C,D). Interestingly, immunohistochemical staining of tumors from the Hic-5<sup>+/-</sup>;PyMT mice revealed that Hic-5 is not significantly expressed in tumor cells (T, inset), but strong staining was observed in the surrounding CAFs within the tumor stroma (S, inset) (Figure 1E). In contrast, paxillin staining was observed in both the stroma (S, inset) and in the tumor cells (T, inset) (Figure 1F).

Immunofluorescence analysis of isolated CAFs revealed that Hic-5 and paxillin localize to focal adhesions (Figure 1G). Strikingly, around 45% of the Hic-5<sup>-/-</sup>;PyMT CAFs exhibited a profound loss of actin towards the center of the cell, while retaining paxillin-positive focal adhesions at the periphery (Figure 1G,H). Western blotting showed that while there is a modest, albeit insignificant increase in paxillin expression in the Hic-5<sup>-/-</sup>;PyMT CAFs (Figure 1I,J) it is insufficient to rescue the loss of Hic-5 function. Taken together, these data suggest that Hic-5 function in the CAFs is playing an indirect, non-cell autonomous role in mammary tumor growth.

### Hic-5 deficiency leads to a reduction in $\alpha$ -SMA positive CAFs

Tumors have been described as wounds that never heal<sup>20</sup>. During wound healing, fibroblasts differentiate into myofibroblasts, similar to during tumor progression where the resident fibroblasts differentiate into highly contractile,  $\alpha$ -SMA positive CAFs<sup>4,21–23</sup>. Hic-5 has previously been shown to be required for myofibroblast differentiation in dermal fibroblasts *in vitro* during wound repair<sup>12,24</sup>. To determine whether genetic ablation of Hic-5 results in fewer  $\alpha$ -SMA positive CAFs in the tumor stroma *in vivo*,  $\alpha$ -SMA staining was performed on Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT tumors sections (Figure 2A). Quantification of the area of positive staining revealed that the Hic-5<sup>-/-</sup>;PyMT tumors have significantly fewer  $\alpha$ -SMA positive CAFs than the heterozygotes (Figure 2B). Furthermore,  $\alpha$ -SMA staining of isolated CAFs also showed a reduction in the number of  $\alpha$ -SMA positive cells derived from the Hic-5<sup>-/-</sup>;PyMT tumors (Figure 2C,D). Importantly, all the cells were also vimentin positive, suggesting that the cells isolated were indeed fibroblasts (data not shown).

Previous reports have also shown that Hic-5 is required for regulating cell contractility<sup>12,13,25</sup>. To assess if Hic-5 expression affects CAF contractility, a collagen gel contraction assay was performed (Figure 2E). The ability of Hic-5<sup>-/-</sup>;PyMT CAFs to contract the collagen gel, in the presence of serum, was significantly reduced as compared to the control CAFs (Figure 2F). Furthermore, the relative level of phosphorylation of Myosin Light Chain-2 (MLC2), a molecular readout of cellular contractility, was also significantly reduced in the Hic-5<sup>-/-</sup>;PyMT CAFs (Figure 2G,H). Taken together, Hic-5 expression/function in the tumor CAFs is necessary for their differentiation and enhanced cellular contractility.

### Hic-5 indirectly regulates tumor cell proliferation and signaling

Tumor volume analysis indicated that Hic-5<sup>-/-</sup>;PyMT tumors grow slower than tumors in littermate controls (Figure 1B), suggesting a possible defect in tumor cell proliferation. Tumor sections were immunostained for Ki67, a proliferation marker, and EPCAM, which selectively labels epithelial cells (Figure 3A). Quantification of the percentage of Ki67 positive cells revealed that there is a >2-fold reduction in the number of proliferating tumor cells in the Hic-5<sup>-/-</sup>;PyMT tumor (Figure 3B), indicating that Hic-5 deficiency in the stroma significantly reduces cellular proliferation in the tumor cells.

CAFs can indirectly regulate tumor cell growth through altered growth factor signaling and by remodeling the stromal matrix<sup>2,26</sup>. For example, increased ECM density and organization has been shown to increase FAK activity in primary tumor cells, as measured by elevated Y397 phosphorylation<sup>27,28</sup>. To assess whether this signaling pathway is influenced by Hic-5 expression, tumor sections from Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT mice were immunostained for FAK pY397 and EPCAM (Figure 3C) and the ratio of FAK pY397 fluorescence intensity to EPCAM fluorescence was quantified. The intensity of FAK pY397 in the tumor cells was significantly reduced in the Hic-5<sup>-/-</sup>;PyMT sections (Figure 3D) and was also reduced in tumor lysates (Figure 3E,F). Interestingly, FAK Y397 phosphorylation was not significantly reduced in the Hic-5<sup>-/-</sup>;PyMT tumor stroma or the isolated CAFs (Supplementary Figure 2A–C). Active FAK regulates multiple cellular functions including the MAPK/ERK pathway to regulate cell proliferation<sup>27</sup>. To determine whether the presence

of Hic-5 in the CAFs also indirectly impacts MAPK signaling, ERK1/2 phosphorylation was assessed by western blotting (Figure 3E). Quantification of ERK1/2 phosphorylation revealed a significant reduction in the Hic-5<sup>-/-</sup>;PyMT tumor lysates, as compared to the heterozygote (Figure 3G).

If Hic-5 functionally regulates stroma-tumor interactions to alter tumor growth, then we would expect to observe no effect on proliferation rates of isolated tumor cells *in vitro*. Consistent with a non-cell autonomous model of Hic-5 function, an XTT proliferation assay analysis revealed no significant differences between the growth rates of the isolated Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT tumor cells (Figure 3H). Taken together, these findings further support a non-cell autonomous role for Hic-5 in the CAFs in promoting tumor cell growth by increasing adhesion-dependent FAK phosphorylation and MAPK activity in tumor cells.

### Hic-5 expression in CAFs is required for ECM deposition and organization

CAFs actively synthesize, deposit and remodel the ECM to promote tumor growth and tumor cell invasion<sup>4</sup>. Given that the Hic-5<sup>-/-</sup>;PyMT tumors have a reduced number of  $\alpha$ -SMA positive CAFs (Figure 2A–D), we assessed whether the Hic-5<sup>-/-</sup>;PyMT CAFs also demonstrate a reduced ability to deposit and organize the tumor ECM. Tumor sections were stained with Masson's trichrome to label fibrillar collagen (Figure 4A). Quantification of the area of positive staining showed that Hic-5<sup>-/-</sup>;PyMT tumors have a reduction in the total amount of fibrillar collagen (Figure 4B). Additionally, the tumor sections were stained for fibronectin (Figure 4C), which was also significantly reduced in the Hic-5<sup>-/-</sup>;PyMT tumors (Figure 4D), suggesting that Hic-5 expression in the tumor stroma is required for matrix deposition.

Cell derived matrices (CDMs) are 3D structures generated by fibroblasts grown at high density *in vitro* for extended periods of time<sup>29</sup>. The resulting matrix scaffolds closely resemble the composition and organization of the *in vivo* stromal microenvironment and therefore provide a useful *in vitro* system to study matrix deposition and organization and subsequently how the ECM influences tumor cell invasive behavior<sup>30,31</sup>. To assess the role of Hic-5 in matrix deposition and organization, *in vitro*, we generated 3D CDMs using the isolated CAFs. Immunofluorescence staining for fibronectin showed that CDMs assembled by the Hic-5<sup>-/-</sup>;PyMT CAFs are less dense, with more spaces between the fibers and of reduced thickness as compared to the CDMs generated by the heterozygote CAFs (Figure 4E,F). Additionally, the angle distribution ( $\Theta$ ) of the fibronectin fibers was quantified, as previously described<sup>31</sup>, revealing that the fibers are more randomly oriented in the Hic-5<sup>-/-</sup>;PyMT CAF-derived CDMs compared to control CDMs (Figure 4G). Furthermore, the ability of the CAFs to remodel the matrix to assemble fibronectin fibrils on a 2D substrate was also significantly reduced in the Hic-5<sup>-/-</sup>;PyMT CAFs (Figure 4H,I). Importantly, the density of the CAF monolayers used to generate the CDMs was not significantly different between the genotypes (Supplementary Figure 3A,B). Taken together, these data indicate that Hic-5 expression in the CAFs is required for optimal ECM deposition and organization.

### Hic-5 is required to organize the matrix for optimal tumor cell migration

The reorganization of the ECM into highly aligned fibers facilitates local invasion of tumor cells into the surrounding stroma *in vivo*<sup>6</sup>. To determine if the disorganization observed in CDMs from Hic-5<sup>-/-</sup>;PyMT CAFs impaired tumor cell migratory behavior, MDA-MB-231 cells, a highly invasive human breast cancer cell line, were plated on CDMs generated from the Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT CAFs (Figure 5A). MDA-MB-231 cells typically exhibit migration plasticity, undergoing frequent transitions between rounded, amoeboid versus elongated, mesenchymal modes of migration<sup>32,33</sup>. The percentage of cells undergoing plasticity was not significantly different between the cells migrating in the Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT CDMs (Figure 5B). However, we observed a higher percentage of MDA-MB-231 cells exhibiting an amoeboid morphology when plated on the Hic-5<sup>-/-</sup> CDMs (Figure 5C). This suggests that the larger gaps between fibers in the Hic-5<sup>-/-</sup>;PyMT-generated CDMs may be more conducive to an amoeboid mode of motility.

Further analysis of tumor cell behavior revealed that MDA-MB-231 cells migrating in the Hic-5<sup>+/-</sup>;PyMT CDM moved linearly along the ECM fibers, with high directionality, whereas the MDA-MB-231 cells that were migrating in the Hic-5<sup>-/-</sup>;PyMT CDM had reduced directionality in accordance with the reduced fiber alignment (Figure 5D,E). Interestingly, migration velocities between the MDA-MB-231 cells in the different CDMs were not significantly different (Figure 5F). Taken together, these data indicate that the Hic-5<sup>-/-</sup>;PyMT CAFs are unable to organize the deposited matrix for optimal tumor cell invasion.

### Hic-5 is required for tumor cell metastasis

The organization of the stromal matrix has also been implicated in promoting metastasis to distant organs<sup>34</sup>. Since Hic-5 is not detectable by immunostaining in tumor cells, we wanted to assess whether the presence/absence of Hic-5 in other tissues, including the tumor stroma may still influence tumor cell invasion and metastasis. Tumor cells upregulate a basal gene program including expression of cytokeratin 14 (CK14) which serves as a useful marker of invasive cells in the primary tumor<sup>35</sup>. Accordingly, tumor sections were stained for CK14 and EPCAM (Figure 6A). The Hic-5<sup>-/-</sup>;PyMT tumors had fewer CK14 positive tumor cells at the tumor-stroma border (Figure 6B). Next, we quantified the number of circulating tumor cells (CTCs), which serves as a readout of whether the tumor cells are able to intravasate into the bloodstream. Consistent with the reduction in CK14 positive tumor cells, blood samples from the Hic-5<sup>-/-</sup>;PyMT mice had a significant reduction in the amount of CTCs (Figure 6C). Furthermore, the Hic-5<sup>-/-</sup>;PyMT mouse lungs had a substantial reduction in the number of metastatic colonies (Figure 6D). Taken together, these data suggest that the microenvironment in the Hic-5<sup>-/-</sup>;PyMT tumors is less favorable for tumor cell invasion and therefore resulting in fewer metastases, possibly due to the reduced density and organization of the tumor stromal matrix.

## DISCUSSION

In this study, we evaluated the role of Hic-5 (TGFβ1i1) in breast tumor progression by crossing our recently generated constitutive Hic-5<sup>-/-</sup> mouse with the MMTV-PyMT



spontaneous breast cancer mouse model. To our knowledge, this model provides the first evidence of a role for Hic-5 in CAF function *in vivo*, and accordingly a non-cell autonomous role for Hic-5 in promoting tumor progression and metastasis through regulation of CAF-mediated deposition and remodeling of the tumor-associated ECM.

Stromal fibroblasts can be induced to differentiate into highly contractile CAFs which can promote tumor growth through remodeling the ECM and paracrine signaling<sup>4</sup>. TGF- $\beta$  signaling through the SMAD family of proteins is required for fibroblast differentiation<sup>36</sup>. Previous studies *in vitro* have implicated Hic-5 in myofibroblast differentiation during hypertrophic scar formation through upregulation of a TGF- $\beta$  autocrine loop<sup>12</sup>. Consistent with this study, we found that there is a reduction in the amount of  $\alpha$ -SMA positive CAFs in the Hic-5<sup>-/-</sup>;PyMT tumor stroma *in vivo* (Figure 2A–D), suggesting that Hic-5 is required for fibroblast differentiation into CAFs, possibly through its direct interactions with SMAD3 and SMAD7<sup>37,38</sup>. TGF- $\beta$  can also serve as a potent inducer of an epithelial-mesenchymal transition (EMT) to promote tumor cell invasion<sup>39</sup>. Interestingly, Hic-5 expression has previously been shown to be required for cultured epithelial cells to undergo a TGF- $\beta$ -induced EMT and subsequent invadopodia formation to acquire an invasive phenotype<sup>17,18</sup>. However, in the current study we did not observe detectable levels of Hic-5 in the tumor cells, suggesting that Hic-5 upregulation in the tumor cells is not required for invasion in this system. Further analysis into how Hic-5 may regulate TGF- $\beta$  production and activity in CAFs and tumor cells will provide mechanistic insight into how Hic-5 may influence stromal/tumor cell crosstalk.

Mechanical feedback loops between the fibroblasts and the ECM promote normal tissue homeostasis through the regulation of intracellular contractility, to exert equal and opposing forces on the ECM<sup>40</sup>. However, changes in ECM density during tumor progression, or increased fibroblast contractility, can promote the upregulation of ECM gene expression, leading to the enhanced deposition and remodeling of the ECM<sup>41–43</sup>. Accordingly, in the absence of Hic-5, we observed reduced collagen and fibronectin deposition within the tumor stroma (Figure 4A–D). Furthermore, the isolated Hic-5<sup>-/-</sup>;PyMT CAFs exhibited a loss of central focal adhesions and stress fibers (Figure 1G,H), were less contractile (Figure 2E–H) and were unable to efficiently assemble fibronectin fibers on their cell surface as compared to controls (Figure 4H,I). However, CAFs can also remodel the stromal matrix through force-independent mechanisms including secretion of matrix metalloproteinases (MMPs), which degrade the ECM, or lysyl oxidases, promoting the crosslinking of collagen fibers and thereby contributing to increased tissue rigidity<sup>9,44</sup>. Accordingly, Hic-5 has been implicated in regulating MMP expression and activity in an abdominal aortic aneurysm model using an independently generated Hic-5<sup>-/-</sup> mouse<sup>45</sup>. Thus, Hic-5 may contribute to stromal matrix organization during tumor progression via both a force-dependent mechanism involving focal adhesion maturation and stress fiber formation and through force-independent mechanisms<sup>46</sup>.

ECM remodeling often results in a stiffer, more organized matrix that has been shown to enhance integrin-mediated signaling by increasing FAK activity to promote tumor cell growth and invasion<sup>28</sup>. It is noteworthy that the tumor cells, unlike the surrounding stroma, in the Hic-5<sup>-/-</sup>;PyMT tumors exhibited reduced FAK Y397 phosphorylation (Figure 3C–E)

and suppressed ERK1/2 activation, which could therefore account for the reduced proliferation measured in the *Hic-5<sup>-/-</sup>;PyMT* tumor. In many cell types, *Hic-5* and its homologue, paxillin, compete for FAK binding to regulate downstream effectors<sup>47</sup>. However, since *Hic-5* is not expressed in the tumor cells, paxillin may be the predominant scaffold for FAK to regulate downstream MAPK signaling. It will be important in future studies to define the respective roles of *Hic-5* and paxillin in CAFs versus tumor cells and to delineate the overlapping and distinct functions of these closely related focal adhesion proteins in breast tumorigenesis.

The *Hic-5<sup>-/-</sup>;PyMT* CAFs assembled a less dense and more disorganized 3D-CDM *in vitro* as compared to control CAFs (Figure 4E). Using the generated CDMs as a model to study *in vivo* matrix density and organization on tumor cell behavior, we observed that the MDA-MB-231 cells did not persistently migrate in the *Hic-5<sup>-/-</sup>;PyMT* CDM while adopting a primarily amoeboid mode of migration (Figure 5C,E)<sup>48</sup>. We speculate that the reduction in circulating tumor cells and metastasis observed in the *Hic-5<sup>-/-</sup>;PyMT* mouse is likely due to a non-cell autonomous effect of *Hic-5* expression in CAFs on tumor cell invasion (Figure 6).

Taken together, our study identifies a key role for *Hic-5* in tumor malignancy through regulation of the tumor microenvironment and supports emerging findings that targeting stromal ECM composition in addition to the tumor itself may be a valid avenue for future therapeutic approaches. It will therefore be important in future studies to understand the mechanism by which *Hic-5* regulates matrix synthesis and organization.

## Material and Methods

### Animals

All mouse experiments were performed in compliance with protocols approved by SUNY Upstate Medical University IACUC. *Hic-5* floxed (*Hic5<sup>F/F</sup>*) mice were generated by the Gene Targeting and Transgenic Facility of the University of Connecticut (Farmington CT, USA). The targeting vector was constructed such that exons 2–7 of *Hic-5* Ensembl transcript, ENSMUST000000167965, were flanked with loxP sites. A Frt-PGK1-Neo-Frt positive selection cassette was inserted 3' to exon 7. The targeting vector was introduced into 129/SvEv embryonic stem cells and homologous recombination was confirmed by G418 positive selection and Gangcyclovir negative selection. Embryonic stem cell aggregation was performed with CD1 morula and the resulting chimeric mice were screened for germline transmission of the targeting vector. The germline chimeric *Hic-5<sup>+F</sup>* mice were then bred to ROSA26-Flp mice to remove the PGK1-Neo cassette. The resulting *Hic-5* floxed mice were then crossed to transgenic HPRT-Cre mice to generate germline deletion of exons 2–7 of *Hic-5* producing the *Hic5* knockout allele. *Hic-5<sup>+/-</sup>* mice were then maintained by backcross to C57BL/6J and intercrossed to generation homozygote mutants. The *Hic-5<sup>-/-</sup>;PyMT* mice were maintained on a mixed genetic background (C57BL/6J and FVB/N). MMTV-PyMT mice were FVB/N and were obtained from Jackson Labs (Bar Harbor, ME). Mice were classified as endpoint when they either reached 14 weeks of age or when any tumor reached 2 cm<sup>3</sup>, whichever came first.



### Tumor latency and growth analysis

Female mice carrying the PyMT transgene were grouped according to genotype and were palpated weekly to determine the age of tumor onset. The long and short axis of the tumors were measured weekly using digital calipers. Tumor volume was calculated using the following formula:  $Volume=(Short\ axis^2)\times(Long\ axis/2)$ . Sample sizes were determined by prior experience using the PyMT mouse model<sup>49</sup>.

### Mammary gland whole mounts

4<sup>th</sup> inguinal mammary glands were prepared for whole mounts as previously described<sup>50</sup>.

### Tumor Cell and CAF Isolation

Cancer associated fibroblasts (CAFs) were collected as a byproduct of a tumor organoid preparation, as previously described<sup>51</sup>. Briefly, tumors were minced and incubated in digestion media (50:50 DMEM:F12, 5% FBS, 5µg/mL Insulin, 50µg/mL Gentamycin, 2mg/mL collagenase, 2mg/mL trypsin) for 30 minutes at 37°C. The cells were centrifuged at 400xg for 10 minutes followed by incubation with 80U of DNase. Differential centrifugation was performed to separate the single CAF cells from tumor organoids. CAFs and tumor cells were then maintained in PyMT media (50:50 DMEM:F12 supplemented with 10% FBS, 2mM L-glutamine, and 10 I.U. penicillin/10µg/mL streptomycin), at 5% CO<sub>2</sub> and 37°C. The cells were routinely tested for mycoplasma by assessing DAPI staining.

### Antibodies and Reagents

Antibodies used were Hic-5, 611164; FAK, 610081; ERK1/2, 610124 (BD Biosciences, Franklin Lakes, NJ, USA); α-SMA, A2547; Fibronectin, F3648; Tubulin, T9026; DAPI, 10236276001 (Sigma Aldrich, St. Louis, MO, USA); phospho-MLC2, 3671; phospho-ERK1/2, 4307 (Cell Signaling Technologies, Danvers, MA, USA); rabbit anti-Ki67, ab15580 (Abcam, Cambridge, MA, USA); FAK pY397, 700255 (ThermoFisher, Waltham, MA, USA); paxillin, ss-5574 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); Cytokeratin-14, PRB-155P (Covance, Princeton, NJ, USA); Rhodamine Phalloidin (Invitrogen, Carlsbad, CA, USA)

The EPCAM antibody, developed by A.G., Farr, was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242

### Immunohistochemistry and immunofluorescence

Tumor sections from endpoint mice were fixed in 4% paraformaldehyde in PBS, embedded in O.C.T. and sectioned. Sections were washed in PBS and blocked in 10% normal goat serum (NGS) for 2 hours. Antibodies were diluted in 10% NGS, washed in PBS+0.1% TX-100 (PBST), followed by incubation with secondary antibody for 2 hours. The slides were washed in PBST, stained with DAPI, and mounted. Sections were imaged using a Zeiss Axioskop2 plus microscope fitted with a Q imaging EXi Blue CCD camera using a Plan-Apochromat 20X/0.75 NA objective. Immunofluorescence staining of cells was performed as previously described<sup>13</sup>.

### Collagen contraction assay

Bovine collagen I (Purecol, Advanced Biomatrix, San Diego, CA) was mixed with 1/10<sup>th</sup> the volume of 10x MEM and brought up to pH 7.0–7.5 using 0.1M NaOH. Two x10<sup>5</sup> Hic-5<sup>+/-</sup>;PyMT or Hic-5<sup>-/-</sup>;PyMT CAFs were embedded into a 500µl collagen gel and polymerized at 37°C. The collagen gels were detached from the tissue culture plastic and either serum free PyMT media or PyMT media supplemented with 10% FBS was incubated with the gel. The percentage that the gel contracted was determined by measuring the diameter of the collagen gels before (0hr) and after (24hr) FBS addition.

### Cell derived matrix generation and migration analysis

Three-dimensional CDMs were generated as previously described<sup>13</sup>. The thickness of the generated CDMs was measured using a Leica SP5 scanning confocal with a HCX PL APO 63×/1.40–0.60 OIL λ BL objective. The orientation of the fibronectin stained fibers was quantified using the OrientationJ plugin for ImageJ<sup>52</sup>. The modal angle, as defined as the angle that had the highest percentage of fibers oriented, was set to 0 to allow for direct comparison between images.

For migration analysis, parental MDA-MB-231 human breast cancer cells (ATCC) were seeded into the generated CDMs for 4 hours in the presence of serum. After 4 hours, time lapse imaging was performed on a Nikon TE2000 microscope equipped with an environmental chamber and imaged using a HCX Plan Fluotar 10×/0.30 NA objective with images taken every 10 minutes for 16 hours. The percentage of cells exhibiting plasticity was assessed by scoring the number of cells undergoing at least one amoeboid to mesenchymal phenotypic switch. The Manual tracking plugin in ImageJ was used to track the cell centroid over the length of the movie. The Chemotaxis and Migration plugin in ImageJ was used to calculate directionality and migration velocity.

### Fibronectin clearing assay

CAFs were plated onto 10µg/mL fibronectin coated glass coverslips and allowed to spread/clear the fibronectin matrix for 4 hours. Images of the cells were acquired using a Leica SP5 scanning confocal with a HCX PL APO 63×/1.40–0.60 OIL λ BL objective. Area of fibronectin fibers was quantified relative to the cell area using ImageJ.

### XTT assay

Tumor cells were plated 24 prior to incubation with XTT reagent in a 96-well dish. The XTT reagent was mixed with phenazine methosulfate immediately before labeling cells and incubated for 2 hours at 37°C and 5% CO<sub>2</sub>. The 450nm absorbance was measured using a Molecular Devices Emax Precision Microplate Reader.

### Isolation of Circulating Tumor Cells

Blood was collected via cardiac puncture of end point mice using heparin sulfate as an anticoagulant. Red blood cells (RBCs) were lysed with RBC lysis buffer (10X stock: 150mM NH<sub>4</sub>Cl, 10mM NaHCO<sub>3</sub>, 1mM EDTA). Cells were centrifuged at 250xg for 7 minutes, washed in 2% FBS in PBS, and centrifuged at 50xg for 5 minutes. The pellet was

resuspended in 500 $\mu$ L PyMT media and added to an 8 $\mu$ m transwell filter and centrifuged at 50xg for 1 minute. The cells remaining on the filter were harvested and counted using a Biorad TC20 Automated Cell Counter with the size gated from 9 $\mu$ m to 40 $\mu$ m.

### ***In vivo* metastasis quantification**

Lungs from endpoint mice were fixed in 10% formalin and embedded in paraffin. Ten micron sections were collected every 250 $\mu$ m and stained using standard H&E. The total number of lung metastases on each section were summed to determine the total number of colonies.

### **Statistical Analysis**

All data were analyzed using a two-sided Student's T-tests using Microsoft Excel or GraphPad Prism software. All data are generated from at least 3 independent mice or experiments. Statistical significance is indicated by \*  $p < 0.05$ . All error bars represent standard error of the mean.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### **Acknowledgments**

We thank members of the Turner lab for critical reading of this manuscript and for insightful discussions. We are grateful to Ian Forsythe for the mouse genotyping and additional technical assistance. We also thank Nicholas Deakin for his assistance in isolating CTCs. This work was supported by the National Institutes of Health Grant R01 CA163096 and R01 GM47607 to C.E.T. R01 NS066071 to E.C.O. and C.E.T., R01 DK083345 to M.K., and the Carol M. Baldwin Breast Cancer Research Fund of CNY awards to C.E.T. and M.K.

### **References**

1. Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and extracellular matrix homeostasis. *Nature Reviews Molecular Cell Biology*. 2014; 15:802–812. [PubMed: 25355505]
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. *Nature Reviews Cancer*. 2006; 6:392–401. [PubMed: 16572188]
3. Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. *Cell*. 2011; 146:148–63. [PubMed: 21729786]
4. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. *International journal of cancer*. 2008; 123:2229–38. [PubMed: 18777559]
5. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Disease models & mechanisms*. 2011; 4:165–78. [PubMed: 21324931]
6. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. *BMC medicine*. 2006; 4:38. [PubMed: 17190588]
7. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. *Breast cancer research*. 2011; 13:223. [PubMed: 22114898]
8. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Reuden CT, et al. Collagen density promotes mammary tumor initiation and progression. *BMC medicine*. 2008; 6:11
9. Levental KR, Yu H, Lakins JN, Egeblad M, Erler JT, Fong SF, et al. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. *Cell*. 2009; 139:891–906. [PubMed: 19931152]

10. Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal adhesions. *Nature reviews Molecular cell biology*. 2009; 10:21–33. [PubMed: 19197329]
11. Thomas SM, Hagel M, Turner CE. Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. *Journal of cell science*. 1999; 112:181–190. [PubMed: 9858471]
12. Dabiri G, Tumbarello DA, Turner CE, Van de Water L. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta1 autocrine loop. *The Journal of investigative dermatology*. 2008; 128:2518–2525. [PubMed: 18401422]
13. Deakin NO, Turner CE. Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. *Molecular biology of the cell*. 2011; 22:327–341. [PubMed: 21148292]
14. Deakin NO, Ballestrem C, Turner CE. Paxillin and Hic-5 interaction with vinculin is differentially regulated by Rac1 and RhoA. *PLoS ONE*. 2012; 7
15. Hagel M, George EL, Klim A, Tamimi R, Opitz SL, Turner CE, et al. The Adaptor Protein Paxillin Is Essential for Normal Development in the Mouse and Is a Critical Transducer of Fibronectin Signaling The Adaptor Protein Paxillin Is Essential for Normal Development in the Mouse and Is a Critical Transducer of Fibronectin. *Molecular and Cellular Biology*. 2002; 22:901–915. [PubMed: 11784865]
16. Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, et al. Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles. *BMC Med Genomics*. 2012; 5
17. Tumbarello DA, Turner CE. Hic-5 Contributes to epithelial-mesenchymal. Transformation Through a RhoA / ROCK-dependent Pathway. 2007; 211:736–748.
18. Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-β-induced epithelial-mesenchymal transition. *Journal of Cell Biology*. 2012; 197:421–437. [PubMed: 22529104]
19. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. *The American journal of pathology*. 2003; 163:2113–26. [PubMed: 14578209]
20. Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. *Nature reviews Molecular cell biology*. 2008; 9:628–38. [PubMed: 18628784]
21. Martin P. Wound healing--aiming for perfect skin regeneration. *Science*. 1997; 276:75–81. [PubMed: 9082989]
22. Hinz B. Formation and function of the myofibroblast during tissue repair. *The Journal of investigative dermatology*. 2007; 127:526–37. [PubMed: 17299435]
23. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. *American Journal of Pathology*. 2012; 180:1340–1355. [PubMed: 22387320]
24. Varney SD, Betts CB, Zheng R, Wu L, Hinz B, Zhou J, et al. Hic-5 is Required for Myofibroblast Differentiation by Regulating Mechanically Dependent, MRTF-A Nuclear Accumulation. *Journal of cell science*. 2016; 129:774–787. [PubMed: 26759173]
25. Kim-Kaneyama JR, Suzuki W, Ichikawa K, Ohki T, Kohno Y, Sata M, et al. Uni-axial stretching regulates intracellular localization of Hic-5 expressed in smooth-muscle cells in vivo. *Journal of cell science*. 2005; 118:937–949. [PubMed: 15713747]
26. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell*. 2005; 121:335–348. [PubMed: 15882617]
27. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. *Oncogene*. 2009; 28:4326–43. [PubMed: 19826415]
28. Paszek MJ, Zahir N, Johnson KR, Latkins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. *Cancer Cell*. 2005; 8:241–254. [PubMed: 16169468]
29. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. *Science*. 2001; 294:1708–1712. [PubMed: 11721053]

30. Kutys ML, Doyle AD, Yamada KM. Regulation of cell adhesion and migration by cell-derived matrices. *Experimental Cell Research*. 2013; 319:2434–2439. [PubMed: 23751565]
31. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. *The American journal of pathology*. 2005; 167:475–488. [PubMed: 16049333]
32. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. *Cell*. 2011; 147:992–1009. [PubMed: 22118458]
33. Friedl P, Wolf K. Plasticity of cell migration: A multiscale tuning model. *Journal of Cell Biology*. 2010; 188:11–19. [PubMed: 19951899]
34. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep*. 2014; 15:1243–1253. [PubMed: 25381661]
35. Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. *Cell*. 2013; 155:1639–51. [PubMed: 24332913]
36. Bieri B, Moses HL. Tumor Microenvironment: TGF $\beta$ : the molecular Jekyll and Hyde of cancer. *Nature reviews Cancer*. 2006; 6:506–20. [PubMed: 16794634]
37. Wang H, Song K, Krebs TL, Yang J, Danielpour D. Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. *Oncogene*. 2008; 27:6791–805. [PubMed: 18762808]
38. Shola DT, Wang H, Wahdan-Alaswad R, Danielpour D. Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8. *Oncogene*. 2012; 31:2480–90. [PubMed: 21996749]
39. Xu J, Lamouille S, Derynck R. TGF- $\beta$ -induced epithelial to mesenchymal transition. *Cell Res*. 2009; 19:156–172. [PubMed: 19153598]
40. Kuo JC. Mechanotransduction at focal adhesions: integrating cytoskeletal mechanics in migrating cells. *Journal of cellular and molecular medicine*. 2013; 17:704–12. [PubMed: 23551528]
41. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nature cell biology*. 2007; 9:1392–400. [PubMed: 18037882]
42. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. *American journal of cancer research*. 2011; 1:482–97. [PubMed: 21984967]
43. Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. *Journal of Cell Biology*. 2012; 196:395–406. [PubMed: 22351925]
44. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer*. 2002; 2:161–174. [PubMed: 11990853]
45. Lei XF, Kim-Kaneyama JR, Arita-Okubo S, Offermanns S, Itabe H, Miyazaki T, et al. Identification of Hic-5 as a novel scaffold for the MKK4/p54 JNK pathway in the development of abdominal aortic aneurysms. *Journal of the American Heart Association*. 2014; 3:e000747. [PubMed: 24811612]
46. Burrige K, Guilluy C. Focal adhesions, stress fibers and mechanical tension. *Experimental Cell Research*. 2016; 343:14–20. [PubMed: 26519907]
47. Nishiya N, Tachibana K, Shibanuma M, Mashimo JI, Nose K. Hic-5-reduced cell spreading on fibronectin: competitive effects between paxillin and Hic-5 through interaction with focal adhesion kinase. *Molecular and cellular biology*. 2001; 21:5332–45. [PubMed: 11463817]
48. Petrie RJ, Doyle AD, Yamada KM. Random versus directionally persistent cell migration. *Nature Reviews Molecular Cell Biology*. 2009; 10:538–549. [PubMed: 19603038]
49. Ouderkirk-Pecone JL, Goreczny GJ, Chase SE, Tatum AH, Turner CE, Krendel M. Myosin 1e promotes breast cancer malignancy by enhancing tumor cell proliferation and stimulating tumor cell de-differentiation. *Oncotarget*. 2016; 24
50. Plante I, Stewart MK, Laird DW. Evaluation of mammary gland development and function in mouse models. *JoVE*. 2011; 53 pii: 2828.
51. Nguyen-Ngoc KV, Shamir ER, Huebner RJ, Beck JN, Cheung KJ, Ewald AJ. 3D Culture Assays of Murine Mammary Branching Morphogenesis and Epithelial Invasion. *Methods in Molecular Biology*. 2015; 1189

52. Rezakhaniha R, Agianniotis A, Schrauwen JT, Griffa A, Sage D, Bouten CV, et al. Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy. *Biomechanics and Modeling in Mechanobiology*. 2012; 11:461–473. [PubMed: 21744269]


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





**Figure 1.**

Hic-5 expression in the stroma is necessary for tumor growth. A) Age of Hic-5<sup>+/-</sup>;PyMT or Hic-5<sup>-/-</sup>;PyMT mice when the first tumor was palpated. Average latency for Hic-5<sup>+/-</sup>;PyMT mice is 51.6 days and 59.6 days for the Hic-5<sup>-/-</sup>;PyMT mice. n=43 Hic-5<sup>+/-</sup>;PyMT mice, n=23 Hic-5<sup>-/-</sup>;PyMT mice. B) Tumor volume is significantly reduced in the Hic-5<sup>-/-</sup> mice. n=36 Hic-5<sup>+/-</sup>;PyMT mice, n=18 Hic-5<sup>-/-</sup>;PyMT mice. (C) Representative western blots of Hic-5 and paxillin staining. (D) Quantification of the relative paxillin expression in whole tumor lysates. n=3 mice of each genotype. (E) Representative immunohistochemistry of Hic-5 staining in tumors from endpoint PyMT mice. The inset shows Hic-5 staining in the stroma (S), but not in the tumor cells (T). n=3 mice of each genotype. (F) Representative paxillin staining in tumors from endpoint mice. Inset shows greyscale image of paxillin staining in the stroma (S) and the tumor cells (T). n=3 mice of each genotype, scale=25µm. (G) Representative staining of Hic-5 and paxillin in isolated CAFs. n=3 independent experiments. (H) Quantification of percentage of cells with a loss of central actin stress fibers. (I) Western blotting of Hic-5 and paxillin in lysates derived from the CAFs and (J)


quantification of the relative paxillin expression. n=4 independent experiments. The data represent the mean  $\pm$  S.E.M., \* p<0.05.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 2.** Hic-5 is required for CAF differentiation and contractility. A) Representative sections of tumors from endpoint mice, immunostained for  $\alpha$ -SMA (dark brown) and hematoxylin (purple). (B) Quantification of the area of  $\alpha$ -SMA positive cells.  $n=4$  mice of each genotype. The slides were blinded prior to analysis. (C) Isolated CAFs were stained for  $\alpha$ -SMA and the resulting quantification (D) of the percentage of  $\alpha$ -SMA positive cells.  $n=3$  independent experiments (E) Collagen gel contraction assay with Hic-5<sup>+/-</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT CAFs and subsequent quantification (F) of the percentage that the gel contracted.  $n=3$  independent experiments. (G) Western blotting for pMLC and (H) quantification of the


relative level of MLC phosphorylation. n=4 independent experiments. The data represent the mean  $\pm$  S.E.M. \* p<0.05.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript

**Figure 3.**

Hic-5 expression in CAFs indirectly regulates tumor cell growth and signaling. A) Representative sections from end point tumors stained with Ki67. B) Quantification of the percentage of Ki67 and EPCAM positive cells. n=4 mice for each genotype. The slides were blinded prior to analysis. C) Representative sections of end point tumors stained for FAK pY397 and EPCAM. The inset shows reduced FAK pY397 fluorescence intensity in the Hic-5<sup>-/-</sup>;PyMT tumor cells, scale=25µm. D) Quantification of the ratio of mean fluorescence intensity (M.F.I.) of FAK pY397 and EPCAM, n=3 mice for each genotype. E) Representative western blots of whole tumor lysates and subsequent quantification of (F) FAK Y397 and (G) ERK 1/2 phosphorylation. n=3 mice of each genotype (H) Cell proliferation *in vitro* was assessed using an XTT assay. n=3 independent experiments. The data represent the mean ± S.E.M. \* p<0.05.





**Figure 4.** Hic-5 expression in the CAFs is required for matrix deposition and organization. A) Representative tumor sections stained with Masson’s trichrome to label fibrillar collagen. B) Quantification of the area of collagen (blue) staining using color thresholding in ImageJ, n=4 mice of each genotype. The slides were blinded prior to analysis. C) Tumor sections stained for fibronectin and (D) quantification of the area of positive staining, n=3 mice of each genotype. E) Representative fibronectin staining of 3D-cell derived matrices (CDMs) F) Thickness measurements of fibronectin stained CDMs measured using confocal microscopy. n=3 independent experiments. G) Fiber angle distribution measurements using




the OrientationJ plugin for ImageJ. The angle distribution of the fibers was quantified by setting the modal angle, as defined as the angle with the highest percentage of fibers aligned, to 0° to allow direct comparison between samples. The data bars represent the percentage of fibers at the indicated angle. n=4 independent experiments (H) Representative images of CAFs plated onto fibronectin coated glass. The arrow shows fibronectin fiber organization on Hic-5+/- CAF (I) Quantification of the area of fibrillar fibronectin relative to the cell area. n=3 independent experiments. The data represent the mean  $\pm$  S.E.M. \* p<0.05.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



**Figure 5.** The Hic-5<sup>-/-</sup>;PyMT CDM organization influences tumor cell migration behavior A) Representative images of MDA-MB-231 cells migrating in CDMs generated from Hic-5<sup>+/+</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT CAFs stained for actin (red) and fibronectin (green). B) Quantification of the percentage of cells that underwent at least one morphology change (plasticity) during the duration of the movie. C) Quantification of the percentage of cells adopting a predominately round, amoeboid phenotype. D) Representative tracks of MDA-MB-231 cells migrating in the Hic-5<sup>+/+</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT CDMs. (E) Quantification of the cell directionality and (F) cell velocity. n=4 independently performed experiments. The data represent the mean ± S.E.M. \* p<0.05.

**Figure 6.**

Mice lacking Hic-5 have reduced metastasis to the lungs. A) Representative sections from Hic-5<sup>+/+</sup>;PyMT and Hic-5<sup>-/-</sup>;PyMT tumors stained for CK14 and EPCAM. B) The area of CK14 staining was quantified, n=4 mice of each genotype C) Quantification of the number of circulating tumor cells in the blood. n= 4 mice for Hic-5<sup>+/+</sup>, n=7 mice for Hic-5<sup>+/+</sup>;PyMT and n=5 mice for Hic-5<sup>-/-</sup>;PyMT. D) The total number of metastatic colonies were manually counted from sections taken every 250μm through of the entire lung, n=6 mice of each genotype. The data represent the mean ± S.E.M. \* p<0.05.